Pluri (PLUR) Non Operating Investment Income (2015 - 2017)
Pluri (PLUR) posted quarterly Non Operating Investment Income of -$78000.0 for Q3 2017, down 2050.0% year-over-year from $4000.0 in Q3 2016, and down 121.14% quarter-over-quarter from $369000.0 in Q2 2017.
Pluri (PLUR) Non Operating Investment Income (2015 - 2017) Analysis & Trends
Pluri (PLUR) has reported Non Operating Investment Income for 3 consecutive years, with -$78000.0 the latest figure, recorded in Q3 2017.
- In Q3 2017, Non Operating Investment Income fell 2050.0% year-over-year to -$78000.0; the TTM figure through Sep 2017 stood at $323000.0 (down 78.54% YoY), while the FY2018 annual figure was -$850000.0, down 309.88% from the prior year.
- Non Operating Investment Income declined to -$78000.0 in Q3 2017 per PLUR's latest filing, from $369000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.5 million in Q2 2015 and bottomed at -$283000.0 in Q1 2016.
- Historically, Non Operating Investment Income has averaged $240444.4 across 3 years, with a median of $16000.0 in 2016.
- On a YoY basis, Non Operating Investment Income climbed as much as 105.65% in 2017 and fell as far as 2050.0% in 2017.
- Pluri's Non Operating Investment Income stood at $1.5 million in 2015, then tumbled by 98.95% to $16000.0 in 2016, then tumbled by 587.5% to -$78000.0 in 2017.
- Business Quant data shows PLUR's Non Operating Investment Income at -$78000.0 in Q3 2017, $369000.0 in Q2 2017, and $16000.0 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | -78,000.00 |
| Sep 30, 2017 | -78,000.00 |
| Jun 30, 2017 | 369,000.00 |
| Jun 30, 2017 | 369,000.00 |
| Mar 31, 2017 | 16,000.00 |
| Mar 31, 2017 | 16,000.00 |
| Dec 31, 2016 | 16,000.00 |
| Dec 31, 2016 | 16,000.00 |
| Sep 30, 2016 | 4,000.00 |
| Sep 30, 2016 | 4,000.00 |
| Jun 30, 2016 | 265,000.00 |
| Jun 30, 2016 | 265,000.00 |
| Mar 31, 2016 | -283,000.00 |
| Mar 31, 2016 | -283,000.00 |
| Jun 30, 2015 | 1.52 Mn |
| Jun 30, 2015 | 1.52 Mn |
| Mar 31, 2015 | 336,000.00 |
| Mar 31, 2015 | 336,000.00 |